Patent · US Active

Treatment of hepatocellular carcinoma characterized by hepatitis B virus infection

US11096940B2 · kind B2 · utility

0Cited by

76References

42Claims

0Family size

Assignee

CELGENE CORPORATION · US

Inventors

Ellen Filvaroff · San Francisco, US
Kristen Mae Hege · Burlingame, US
Shaoyi Li · 红钢城街道, CN

Key dates

Filing date	Jun 21, 2018
Grant date	Aug 24, 2021
Priority date	—
Expiry date	Jun 21, 2038

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61K2039/505
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Provided herein are methods for treating and/or preventing hepatocellular carcinoma (HCC) characterized by hepatitis B virus (HBV) infection in a patient, comprising administering an effective amount of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one or a pharmaceutically acceptable salt or tautomer thereof (collectively referred to herein as “Compound 1”) to the patient having HCC characterized by HBV infection.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.